...
首页> 外文期刊>Vaccine >Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model
【24h】

Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model

机译:分子佐剂IL-33在致命的攻击模型中增强了DNA疫苗的效力

获取原文
获取原文并翻译 | 示例
           

摘要

Identifying new molecular adjuvants that elicit effective vaccine-induced CD8(+) T cell immunity may be critical for the elimination of many challenging diseases including Tuberculosis, HIV and cancer. Here, we report that co-administration of molecular adjuvant IL-33 during vaccination enhanced the magnitude and function of antigen (Ag)-specific CD8(+) T cells against a model Ag, LCMV NP target protein. These enhanced responses were characterized by higher frequencies of Ag-specific, polyfunctional CD8(+) T cells exhibiting cytotoxic characteristics. Importantly, these cells were capable of robust expansion upon Ag-specific restimulation in vivo and conferred remarkable protection against a high dose lethal LCMV challenge. In addition, we demonstrate the ability of IL-33 to amplifying the frequency of Ag-specific KLRG1(+) effector CD8(+) T cells. These data show that IL-33 is a promising immunoadjuvant at improving T cell immunity in a vaccine setting and suggest further development and understanding of this molecular adjuvant for strategies against many obstinate infectious diseases and cancer. (C) 2015 Elsevier Ltd. All rights reserved.
机译:鉴定引发疫苗诱导的有效CD8(+)T细胞免疫力的新分子佐剂对于消除包括结核病,HIV和癌症在内的许多具有挑战性的疾病可能至关重要。在这里,我们报告说,疫苗接种过程中分子佐剂IL-33的共同给药增强了针对模型Ag,LCMV NP目标蛋白的抗原(Ag)特异性CD8(+)T细胞的大小和功能。这些增强的反应的特点是更高频率的Ag特异性,多功能CD8(+)T细胞表现出细胞毒性特征。重要的是,这些细胞能够在体内进行Ag特异性再刺激后强劲扩增,并针对高剂量致命性LCMV攻击提供出色的保护。此外,我们证明了IL-33能够放大Ag特异性KLRG1(+)效应CD8(+)T细胞的频率。这些数据表明,IL-33是提高疫苗环境中T细胞免疫力的有前途的免疫佐剂,并建议对该分子佐剂进行进一步开发和了解,以应对许多顽固性传染病和癌症。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号